Unproven Stem Cell-Based Interventions: Advancing Policy through Stakeholder Collaboration.
作者信息
Matthews Kirstin R W, Iltis Ana S
出版信息
Tex Heart Inst J. 2017 Jun 1;44(3):171-173. doi: 10.14503/THIJ-17-6244. eCollection 2017 Jun.
Abstract
摘要
相似文献
1
Unproven Stem Cell-Based Interventions: Advancing Policy through Stakeholder Collaboration.
Tex Heart Inst J. 2017 Jun 1;44(3):171-173. doi: 10.14503/THIJ-17-6244. eCollection 2017 Jun.
2
Unproven stem cell interventions: A global public health problem requiring global deliberation.
Stem Cell Reports. 2021 Jun 8;16(6):1435-1445. doi: 10.1016/j.stemcr.2021.05.004.
3
Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
BMC Med Ethics. 2019 Aug 6;20(1):51. doi: 10.1186/s12910-019-0388-4.
4
A RAT by Another Name: 21 Century Cures Act and Stem Cell Therapies.
Am J Law Med. 2018 May;44(2-3):291-308. doi: 10.1177/0098858818789427.
5
Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
Stem Cell Reports. 2021 Jun 8;16(6):1425-1434. doi: 10.1016/j.stemcr.2021.04.017. Epub 2021 May 20.
6
Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.
Lancet Oncol. 2018 May;19(5):e267-e274. doi: 10.1016/S1470-2045(18)30097-4.
7
The cell based therapy and the policy implications in India.
J Stem Cells. 2011;6(3):155-79.
8
When right beats might.
Nature. 2015 Feb 26;518(7540):455. doi: 10.1038/518455a.
9
Legal and ethical status of stem cells as medicinal products.
Adv Drug Deliv Rev. 2005 Dec 12;57(13):1970-80. doi: 10.1016/j.addr.2005.08.005. Epub 2005 Nov 16.
10
FDA should stand firm on stem-cell treatments.
Nature. 2016 Jul 7;535(7610):7-8. doi: 10.1038/535007b.
引用本文的文献
1
Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward.
Front Bioeng Biotechnol. 2021 Dec 16;9:789043. doi: 10.3389/fbioe.2021.789043. eCollection 2021.
2
Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential.
Stem Cell Reports. 2021 Aug 10;16(8):1847-1852. doi: 10.1016/j.stemcr.2021.07.003. Epub 2021 Jul 29.
3
The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
BMC Med Ethics. 2018 May 2;19(1):32. doi: 10.1186/s12910-018-0273-6.
本文引用的文献
1
Regulation: Rewriting the regenerative rulebook.
Nature. 2016 Dec 7;540(7632):S64-S67. doi: 10.1038/540S63a.
2
Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
Cell Stem Cell. 2016 Aug 4;19(2):154-157. doi: 10.1016/j.stem.2016.06.007. Epub 2016 Jun 30.
3
Policy: Global standards for stem-cell research.
Nature. 2016 May 19;533(7603):311-3. doi: 10.1038/533311a.
4
Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.
Stem Cell Reports. 2016 Jun 14;6(6):787-797. doi: 10.1016/j.stemcr.2016.05.001. Epub 2016 May 12.
5
Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders.
BMC Med Ethics. 2015 Nov 4;16(1):75. doi: 10.1186/s12910-015-0069-x.
6
U.S. National Football League athletes seeking unproven stem cell treatments.
Stem Cells Dev. 2014 Dec;23 Suppl 1(Suppl 1):60-4. doi: 10.1089/scd.2014.0358.
7
Randomised controlled trials for Ebola: practical and ethical issues.
Lancet. 2014 Oct 18;384(9952):1423-4. doi: 10.1016/S0140-6736(14)61734-7. Epub 2014 Oct 13.
8
Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.
BMC Med Ethics. 2014 Oct 14;15:75. doi: 10.1186/1472-6939-15-75.
9
Stem cell tourism and public education: the missing elements.
Cell Stem Cell. 2014 Sep 4;15(3):267-270. doi: 10.1016/j.stem.2014.08.009.
10
Effective messages in vaccine promotion: a randomized trial.
Pediatrics. 2014 Apr;133(4):e835-42. doi: 10.1542/peds.2013-2365. Epub 2014 Mar 3.
Zotero 插件